Receive two exclusive white papers from Volv Global
Volv Global will release two insightful white papers in the coming months, offering paradigm shifts and strategies for rare disease treatment and healthcare collaboration. Select the white paper(s) that interest you and register to receive them upon publication!
.png?width=350&height=350&name=Design%20sans%20titre%20(26).png "Design sans titre (26)")
Fill out the form below to register and receive our upcoming white papers
Overview of our upcoming white papers
Drive For Change
Expected publication date: Q2 2025
Paradigm shifts and strategic recommendations to overcome barriers in orphan drug development
The orphan drug development landscape is fraught with significant barriers, including small patient populations, high R&D costs, and biological complexity. This paper presents strategic recommendations to overcome these barriers by proposing paradigm shifts in three key areas: population size estimation, understanding of disease biology, and assessing the true cost and burden of rare diseases. Based on industry workshops, surveys, and case studies, these recommendations aim to foster greater collaboration, enhance investment, and leverage innovative technologies to accelerate orphan drug development.
ElevateHealth
Expected publication date: Q2 2025
Creating real impact for rare disease patients
How can stakeholders in the healthcare ecosystem solve the complexity together?
With Elevate Health, Volv Global and Novartis are initiating a Big Picture conversation on how the healthcare ecosystem can optimise patient outcomes and the patient journey, taking particular aim at those issues which arise from insufficient coordination across stakeholders and across differences of scale. This “ElevateHealth” project will attempt to create better understanding of the complex structural and systemic dynamics in the ecosystem based on a three-level concept of interactions: (1) The “Micro” level of the individual, (2) The “Meso” level of healthcare resources, and (3) The “Macro” level of healthcare provision. This white paper will summarise the learnings from Volv Global’s workshop at the World Orphan Drug Congress Europe 2024, focussed very tightly on the barriers to adoption of new technology solutions that can add significant value to the healthcare ecosystem. E.g., to improve the diagnosis pathway, access to care, clinician workload and impact on healthcare system for rare diseases. Alongside Novartis’ separate workshop, we intend to generate a framework which might help to better navigate the healthcare ecosystem’s complexity together, including the digital tools that may help.